Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of April 2019, specifically reporting on a registered direct offering of American Depositary Shares (ADSs) entered into on April 2, 2019, with an expected closing date of April 4, 2019.
Key Financial Metrics
- Gross Proceeds: Approximately $3,200,000 from the issuance of 4,923,078 ADSs at $0.65 per share.
- Shareholder Equity: The Company believes its shareholders' equity is above $6.0 million upon receipt of proceeds and considering results of operations for the quarter ended March 31, 2019.
- Transaction Costs: A cash placement fee of 6% of the aggregate purchase price, a non-accountable expense allowance of $50,000, and clearing expenses of $10,000 payable to H.C. Wainwright & Co., LLC.
- Warrant Terms: Investors received warrants to purchase 4,923,078 ADSs at an exercise price of $0.86 per ADS, expiring five years from issuance. Placement agent warrants equal to 5% of ADSs sold were also issued.
Material Changes
The primary material change is the dilution of existing shareholders through the issuance of new ADSs and warrants. The Company has agreed to a 60-day lock-up period on issuing new securities and a 13-month restriction on "variable rate transactions" following the closing of the offering.
Outlook, Risks, and Contingencies
- Closing Contingency: The offering is subject to customary closing conditions; failure to satisfy these may prevent the transaction from closing.
- Registration Obligation: The Company must file a registration statement for the resale of warrant shares by May 2, 2019, and use best efforts to have it declared effective within 60 days of closing.
- Forward-Looking Statements: The filing includes standard warnings that future events, including the closing of the offering, are not guaranteed and depend on conditions beyond the Company's control.
Investor Verification Checklist
- Confirm the actual closing date of the offering and whether all customary conditions were satisfied.
- Verify the filing and effectiveness date of the registration statement for the warrant shares (deadline: May 2, 2019 for filing).
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Warrant (Exhibit 10.2) for specific adjustment provisions and cashless exercise terms.
- Monitor the Company's cash burn rate to assess the runway provided by the $3.2 million gross proceeds.